{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:05:49Z","timestamp":1789693549626,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,10]],"date-time":"2027-08-10T00:00:00Z","timestamp":1817856000000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1U10 CA180822"],"award-info":[{"award-number":["1U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:16:46Z","timestamp":1786389406000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor"],"prefix":"10.1016","volume":"212","author":[{"given":"Elizabeth E.","family":"Hopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Enserro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Chitiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.07.017_bb0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/er.2011-0014","article-title":"Molecular pathogenesis of granulosa cell tumors of the ovary","volume":"33","author":"Jamieson","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0010","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0015","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1530\/JME-13-0159","article-title":"FOXL2: a central transcription factor of the ovary","volume":"52","author":"Georges","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0020","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0025","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1951::AID-CNCR16>3.0.CO;2-U","article-title":"Prognostic factors in adult granulosa cell tumor of the ovary","volume":"79","author":"Miller","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1701-2163(16)30464-9","article-title":"Granulosa cell tumour: a recurrence 40 years after initial diagnosis","volume":"27","author":"East","year":"2005","journal-title":"J. Obstet. Gynecol. Can. JOGC"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/07853890.2017.1294760","article-title":"Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary","volume":"49","author":"F\u00e4rkkil\u00e4","year":"2017","journal-title":"Ann. Med."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2024.10.019","article-title":"Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: the GREKO III study (GETHI2016-01)","volume":"191","author":"Garc\u00eda-Donas","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.06.026","article-title":"Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer","volume":"189","author":"Andres","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3346\/jkms.2009.24.3.535","article-title":"GnRH agonist therapy in a patient with recurrent ovarian granulosa cell tumors","volume":"24","author":"Kim","year":"2009","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0060","first-page":"393","article-title":"Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor","volume":"41","author":"Fishman","year":"1996","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biocel.2016.01.003","article-title":"Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors","volume":"72","author":"Leung","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0303-7207(03)00235-1","article-title":"The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein","volume":"206","author":"Ellsworth","year":"2003","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0075","article-title":"Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors","volume":"8","author":"Cheng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0090","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ijgc-2018-000065","article-title":"Emerging biomarkers in ovarian granulosa cell tumors","volume":"29","author":"Mills","year":"2019","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer. Soc."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/PGP.0000000000001032","volume":"43","author":"Moh","year":"2024","journal-title":"Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/07357907.2025.2599380","article-title":"Combination hormonal drug therapy inhibits in vitro growth of adult ovarian granulosa tumor cells","volume":"44","author":"Summey","year":"2026","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0105","article-title":"A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor","volume":"44","author":"Summey","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0110","doi-asserted-by":"crossref","unstructured":"Garcia-Donas J, Hurtado A, Garrigos L, Santaballa A, Redondo A, Vidal L, Lainez N, Guerra E, Rodriguez V, Cueva J, Bover I, Palacio I, Rubio MJ, Prieto M, Lopez-Guerrero JA, Rodriguez-Moreno JF, Garcia-Casado Z, Garcia-Martinez E, Taus A, de Castro IP, Navarro P, Grande E, Spanish Group for Research in Orphan, Infrequent Tumors (GETHI). Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011\u201303. Clin. Transl. Oncol. 2023;25:2090\u20138, https:\/\/doi.org\/10.1007\/s12094-023-03085-w.","DOI":"10.1007\/s12094-023-03085-w"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0115","first-page":"3223","article-title":"Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)","volume":"27","author":"Garcia-Donas","year":"2025","journal-title":"Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100005","article-title":"Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary","volume":"35","author":"Finch","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/gyno.1998.5304","article-title":"Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study","volume":"72","author":"Homesley","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2024.09.002","article-title":"Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: an NRG oncology\/gynecologic oncology group study14","volume":"190","author":"Brown","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2005.01.011","article-title":"The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2015.11.027","article-title":"A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG oncology\/gynecologic oncology group study","volume":"140","author":"Burton","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0150","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.07.017_bb0155","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2026.07.017_bb0160","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:41:21Z","timestamp":1789692081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S0090825826020755"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}